FB2026_01 , released March 12, 2026
FB2026_01 , released March 12, 2026
Reference Report
Open Close
Reference
Citation
Angeles, D.C., Ho, P., Dymock, B.W., Lim, K.L., Zhou, Z.D., Tan, E.K. (2016). Antioxidants inhibit neuronal toxicity in Parkinson's disease-linked LRRK2.  Ann. Clin. Transl. Neurol. 3(4): 288--294.
FlyBase ID
FBrf0232002
Publication Type
Research paper
Abstract
Mutations in leucine-rich repeat kinase-2 are the most common cause of familial Parkinson's disease. The prevalent G2019S mutation increase oxidative, kinase and toxic activity and inhibit endogenous peroxidases. We initially screened a library of 84 antioxidants and identified seven phenolic compounds that inhibited kinase activity on leucine-rich repeat kinase-2 substrates. The representative antioxidants (piceatannol, thymoquinone, and esculetin) with strong kinase inhibitor activity, reduced loss in dopaminergic neurons, oxidative dysfunction, and locomotor defects in G2019S-expressing neuronal and Drosophila models compared to weak inhibitors. We provide proof of principle that natural antioxidants with dual antioxidant and kinase inhibitor properties could be useful for leucine-rich repeat kinase-2-linked Parkinson's disease.
PubMed ID
PubMed Central ID
PMC4818746 (PMC) (EuropePMC)
Associated Information
Comments
Associated Files
Other Information
Secondary IDs
    Language of Publication
    English
    Additional Languages of Abstract
    Parent Publication
    Publication Type
    Journal
    Abbreviation
    Ann. Clin. Transl. Neurol.
    Title
    Annals of clinical and translational neurology
    ISBN/ISSN
    2328-9503
    Data From Reference
    Alleles (4)
    Genes (2)
    Human Disease Models (1)
    Transgenic Constructs (3)